Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436)

PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently demonstrated improved progression free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. The current study examined potential genetic markers associated with response and PFS in the ph...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Nathanson, Katherine L., Martin, Anne-Marie, Wubbenhorst, Bradley, Greshock, Joel, Letrero, Richard, D’Andrea, Kurt, O’Day, Steven, Infante, Jeffrey R., Falchook, Gerald S., Arkenau, Hendrik-Tobias, Millward, Michael, Brown, Michael P., Pavlick, Anna, Davies, Michael A., Ma, Bo, Gagnon, Robert, Curtis, Martin, Lebowitz, Peter F., Kefford, Richard, Long, Georgina V.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3924894/
https://ncbi.nlm.nih.gov/pubmed/23833299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0827
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares